A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

At a major cancer conference, Merck rolled out some showstoppers — data on drugs on which its business future may depend.

Immutep ( ($IMMP) ) has shared an announcement. On October 20, 2025, Immutep Limited presented two posters at the ESMO Congress 2025, showcasing ...

A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...

Immutep Ltd ( ($AU:IMM) ) has provided an announcement. Immutep Limited has announced promising results from its INSIGHT-003 trial, presented at ...

Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...

IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with ...

Safety results showed no increase in immune-mediated adverse events (34.0% vs 38.4%) or treatment-related adverse events ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...

CStone Pharmaceuticals ( OTCPK:CSPHF) Discusses CS2009 Data Interpretation and Future Clinical Development Strategy October 20, 2025 9:00 AM EDT ...